Ipsogen gets microarray license:
This article was originally published in Clinica
French molecular diagnostics specialist Ipsogen has gained non-exclusive worldwide rights to Affymetrix's microarray technology to incorporate into its in vitro diagnostic (IVD) tests. Ipsogen (headquartered in Marseille) will develop IVDs initially for breast cancer. Financial details of the deal were not disclosed.
You may also be interested in...
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.
Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.